Pentixapharm Shifts Focus to Clinical Advancement and Strengthens Finances

Pentixapharm Holding AG is redirecting its strategic focus towards advanced clinical programs while discontinuing preclinical activities. This decision marks a significant restructuring aimed at bolstering financial stability. The company's Managing and Supervisory Boards have collectively decided to concentrate resources on the CXCR4 flagship program, which is Phase 3-ready.

The shift includes a substantial reduction of early-stage R&D activities and a reorganization of the company's structure. As part of this realignment, Pentixapharm plans to reduce its workforce by approximately 50%. These changes are expected to decrease operational costs and extend financial viability through Q1 2027.